Section
Recent clinical evidence demonstrates that endoscopic and arthroscopic techniques for infraclavicular brachial plexus neurolysis and pectoralis minor release provide comparable outcomes to open surgery with significantly reduced morbidity f
This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.
This study demonstrates that while MS genetic risk factors are largely shared across ancestral groups, their predictive power and population-level impact vary significantly between European, South Asian, and African populations.
This review evaluates a recent 2-year pilot RCT on low-dose lithium carbonate for MCI, synthesizing its findings with emerging evidence on Aβ clearance, gut-brain axis modulation, and multimodal disease forecasting.
The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical dev
A large-scale retrospective study reveals that anxiety and depression following the diagnosis of unruptured intracranial aneurysms significantly increase the risk of rupture and all-cause mortality, suggesting that integrated psychiatric as
Researchers have discovered that mutations in the SNUPN gene cause spinocerebellar atrophy by disrupting RNA splicing in Purkinje cells, expanding the understanding of neurodevelopmental disorders beyond muscular conditions.
This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
This article examines a Phase 2a trial investigating eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to recruitment challenges, the study provides a critical framework for future antie
This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention&#
The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a
A large-scale individual patient data meta-analysis reveals that while systemic embolic events are less common than strokes in atrial fibrillation, they carry an equivalent mortality risk. NOACs significantly reduce this risk by 29% compare
A secondary analysis of the ARCADIA trial reveals a surprising inverse relationship: prolonged QTc intervals were associated with a significantly reduced risk of recurrent stroke in patients with atrial cardiopathy, challenging existing par
This cross-sectional study of 2,268 autopsies reveals that female sex, APOEε4 status, and African ancestry independently and jointly influence neuritic plaque burden, suggesting that current Alzheimer’s biomarker thresholds may need refinem
This review explores a groundbreaking study using normative modeling and morphometric similarity networks to identify three distinct neurobiological biotypes of ADHD, providing a framework for precision psychiatry.
This article examines the 20-year safety and efficacy of transcatheter PFO closure in patients with paradoxical embolism, highlighting low recurrence rates but significant long-term bleeding risks associated with antithrombotic therapy.
The EMPHASIS trial reveals that oral minocycline initiated within 72 hours of an acute ischaemic stroke significantly enhances functional independence at 90 days. This multicentre study provides robust evidence for a well-tolerated, accessi
The Phase 3 CIFFREO trial for the gene therapy fordadistrogene movaparvovec failed to meet its primary efficacy endpoint in boys with Duchenne muscular dystrophy, showing no significant functional improvement over placebo and leading to the
The BIA-2093-213 trial evaluated eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to being underpowered, the study establishes a feasible framework for future antiepileptogenesis resear
